Portfolio Lab

Protagonist Therapeutics, Inc

  • Stock
  • Ticker PTGX
  • Nasdaq

Health care · Pharmaceuticals · USA

$121.40 −2.11%
Close of 20 Nov 2026
Open in backtest

Performance, volatility and drawdowns of Protagonist Therapeutics, Inc since 11/2016, with distributions reinvested and calculated in US dollars. As of 20 Nov 2026.

Performance

PTGXGlobal equities (VT)

$10,000 grew to $48,175. Global equities (VT): $29,042.

Distributions reinvested, before taxes and brokerage costs. Dashed: Global equities (VT) for comparison.

Declines from the peak

Lowest point −85.8% in 06/2022, measured from the peak in 09/2021. It took 42 months to get back to the old peak.

1-year return
+44.2%
5-year return p.a.
+28.2%
10-year return p.a.
+17.0%
Volatility p.a.
83.0%
Largest decline
−85.8%

Financial statements

Amounts in $ millions from filings with the SEC, earnings per share in $; fourth quarter and quarterly cash flow derived from year-to-date figures

Quarter end12/202403/202506/202509/202512/202503/202606/202609/2026
Income statement
Revenue171285.54.77.456213274
Gross profit–––––––273
Operating income127-19-42-46-50-3.6159218
EBITDA127-19-42-46-50-3.2159219
Net income132-12-35-39-443.8163220
Earnings per share2.01-0.19-0.55-0.62-0.700.052.293.07
Balance sheet
Total assets7457427187026686978861,147
Liabilities6953505653424462
Equity6756896686456156558421,085
Cash97140169114128194420498
Cash flow
Operating cash flow-29125-29-1.9-37-49219-23
Capital expenditure-0.3-0.5-0.8-0.1-0.1-0.2-0.2-0.2
Free cash flow-29125-30-2.0-37-49219-23

Value it:DCF calculatorMultiples calculator

Annual returns

Best year 2020 at +186.0%, weakest 2022 at −68.1%. 6 of 9 full years were positive. * partial year.

Quarterly reports

Filing date with the SEC and earnings per share of the quarter

DayEarnings per share
6 Nov 2026$3.07
5 Aug 2026$2.29
5 May 2026$0.05
25 Feb 2026−$0.70
6 Nov 2025−$0.62
6 Aug 2025−$0.55
6 May 2025−$0.19
21 Feb 2025$2.01
7 Nov 2024−$0.54
6 Aug 2024−$0.50
7 May 2024$3.26
27 Feb 2024$0.52

Key metrics

Metrics of 15 Nov 2026; P/E, P/B, P/S, market cap and dividend yield at the last close.

Valuation

Market cap
€7.2bn
Market cap in trading currency
$7.92bn
Enterprise value
$7.12bn
P/E
25.8
P/S
14.36
P/B
7.30
EV/Sales
12.91
EV/EBITDA
21.9
Earnings yield
3.9%
FCF yield
1.4%

Results (last four quarters)

Revenue
$552m
Gross profit
–
EBITDA
$325m
Net income
$342m
Earnings per share
$4.71
Revenue per share
$8.45
Revenue growth
+5,723.6%
Earnings growth
–

Profitability

Gross margin
–
Operating margin
58.6%
Net margin
62.0%
Return on equity
39.6%
Return on assets
29.9%

Balance sheet and cash flow

Cash
$800m
Cash per share
$12.26
Financial debt
–
Debt/equity %
–
Current ratio
19.85
Book value per share
$16.62
Operating cash flow
$110m
Free cash flow
$109m

Dividend

Dividend yield
0.00%
Dividend (12 months)
$0.00
Yield (12 months)
0.00%
Payout ratio
0%
Ex-dividend date
–

Shares and trading

Shares outstanding
65.3m
Volume
600,711
Avg. volume 3 months
670,345
Relative volume
0.9

Price and technicals

Price
$121.40
1 day
−2.1%
52-week high
$158.62
52-week low
$79.73
Distance to 52-week high
−23.5%
Distance to 52-week low
+52.3%
Distance to 50-day line
−12.1%
Distance to 200-day line
+0.9%
RSI (14)
32
Volatility 1M
37.3%

Performance

1 week
−7.3%
1 month
−13.0%
3 months
−21.5%
6 months
+22.4%
YTD
+39.0%
1 year
+42.6%

Dates

Fiscal year end
31 Dec 2025
Most recent quarter
30 Sep 2026

Frequently asked questions

How has PTGX performed since 11/2016?

$10,000 grew to $48,175 by 20 Nov 2026, which is +17.0% per year. Distributions are reinvested; taxes and brokerage costs are not deducted.

How volatile is PTGX?

Volatility was 83.0% per year, measured on monthly returns. The largest decline from a peak was −85.8%, with the low in 06/2022.

How does PTGX compare with a broad equity ETF?

Over the same period Global equities (VT) returned +11.3% per year at 15.1% volatility, PTGX returned +17.0% at 83.0%. The correlation of monthly returns was 0.31; 1 would mean they moved in lockstep.

Which currency are the figures in?

In US dollars, the currency of the US listing.

Not investment advice. Metrics and financial statements calculated from the company's mandatory filings with the SEC, without guarantee; amounts in US dollars.

Reference data of securities: source ESMA (FIRDS reference data) and SEC (EDGAR).

Not investment advice: results in Portfolio Lab are model calculations based on historical data and your inputs. Past performance is not a reliable indicator of future results.

Protagonist Therapeutics, Inc (PTGX): Return and risk